RGD-Modified PEG-PAMAM-DOX Conjugate: In Vitro and In Vivo Targeting to Both Tumor Neovascular Endothelial Cells and Tumor Cells

Authors

  • Saijie Zhu,

    1. Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China
    Search for more papers by this author
  • Lili Qian,

    1. Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China
    Search for more papers by this author
  • Minghuang Hong,

    1. Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China
    Search for more papers by this author
  • Lihong Zhang,

    1. Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China
    Search for more papers by this author
  • Yuanying Pei,

    1. Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China
    Search for more papers by this author
  • Yanyan Jiang

    Corresponding author
    1. Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China
    • Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, Ministry of Education and PLA School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, P. R. China.
    Search for more papers by this author

Abstract

original image

A novel multifunctional drug–polymer conjugate is prepared. RGD peptide is used to actively target the drug delivery system to tumor neovascular endothelial cells and tumor cells, while the PEG-PAMAM polymeric carrier permits passive targeting to the tumor site by the enhanced permeability and retention (EPR) effect. Controlled release of the anticancer drug doxorubicin is also achieved via acid-sensitive cis-aconityl linkage.

Ancillary